Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Galux Signs Research Agreement with Boehringer Ingelheim to Enhance AI-Driven Protein Design.
Dec 17, 2025
Contract Type
agreement
SeoulBiotechnologyArtificial Intelligence
Description
Galux has announced a research agreement with Boehringer Ingelheim to jointly explore AI's application in precision protein design for therapeutic development. The collaboration aims to design specific protein molecules that solve complex scientific and translational challenges in drug development.
Company Information
Company
Galux
Location
Seoul, Seoul, South Korea
About
Galux is a South Korean biotech company that specializes in AI-driven protein therapeutics discovery. The company is focused on developing innovative solutions for precise protein design in therapeutic applications. Its advanced AI platforms aim to tackle challenges in molecular design and optimize the development of targeted therapies.